Current Report · Items 8.01 · 8-K

Oncolytics Biotech, Inc.

ONCYNASDAQEQUITYCurrent

Other Events

Filed Aug 18, 2026Accepted Aug 18, 2026, 9:03 AM EDTCIK 1129928Accession 0001129928-26-000053

Company context

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.

Current securities

ONCYNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 8.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events

Item 8.01. Other Events. On August 18, 2026, Oncolytics Biotech Inc. (the “Company”) issued a press release announcing feedback from the U.S. Food and Drug Administration related to the planned pivotal Part B expansion of the REO 033 colorectal cancer study and other planned study design elements. The information set forth in this Item 8.01 and in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Get the free weekly BCS email.